Physician profile
Michael A Sty
NPI 1649223181
$888.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $279 · 2021: $142.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $236.41 | 2019-2021 | |
| Pfizer INC. | $145.64 | 2019-2020 | |
| Novo Nordisk INC | $103.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.50 | 2019-2021 | |
| Lilly USA, LLC | $61.50 | 2020 | |
| Allergan, INC. | $56.72 | 2020 | |
| Merck Sharp & Dohme LLC | $51.61 | 2019-2021 | |
| Abbott Laboratories | $38.89 | 2019 | |
| Amarin Pharma, INC. | $33.58 | 2020-2021 | |
| Amgen INC. | $27.98 | 2019 | |
| Promius Pharma LLC | $19.25 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.56 | 2021 | |
| Glaxosmithkline, LLC. | $12.95 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.